In the crowded biotech landscape, most startups burn through millions chasing a single drug candidate. AcuImmune is taking a contrarian approach: they're a lean, 4-person operation generating $600k in revenue while focusing on the critical pre-clinical phase. This isn't a story about flashy funding rounds—it's about solving a fundamental bottleneck in drug development.

"AcuImmune proves that in biotech, revenue beats funding when you solve the right problem at the right time."

• 4-person team with focused expertise in cellular immunogenicity
• Revenue-first model without external funding pressure
• WordPress/Tailwind stack suggests modern, low-overhead tech approach
• Zero web traffic indicates pure B2B referral business
• LocalBusiness structured data suggests physical presence and local relationships

The tech stack reveals their philosophy: WordPress with Tailwind CSS and Bootstrap. This isn't a company spending $50k on a custom web platform—they're pragmatic builders. The site does its job: provides information, captures leads via [email protected], and gets out of the way. In biotech, where scientific credibility matters more than flashy UX, this minimalist approach makes perfect sense.